Related Research Articles
Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..
Dexrazoxane hydrochloride is a cardioprotective agent. It was discovered by Eugene Herman in 1972. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH.
Jane Ellen Henney is an American physician who was the first woman to serve as commissioner of the U.S. Food and Drug Administration. Appointed by President Bill Clinton, she served at the FDA from 1999 to 2001.
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.
Emil J. Freireich was an American hematologist, oncologist, and cancer biologist. He was recognized as a pioneer in the treatment of cancer and use of chemotherapy and is often known as the father of modern leukemia therapy.
Stephen Michael Hahn is an American physician who served as the Commissioner of Food and Drugs from 2019 to 2021. Before becoming Commissioner, he was an oncologist serving as Chief Medical Executive of the MD Anderson Cancer Center. In 2021 he became Chief medical officer at the venture capital firm that launched Moderna.
Jonathan W. Simons is an American physician-scientist, medical oncologist, and leader in prostate cancer research. In August 2021, Simons was appointed the medical director and Chief Science Officer of the Marcus Foundation. Prior to joining the Marcus Foundation, he served a 14-year tenure as the President and chief executive officer of the Prostate Cancer Foundation. Simons’ laboratories, partly funded by the Prostate Cancer Foundation, at Johns Hopkins University and Emory University made original contributions to understanding the molecular biology of prostate cancer metastasis and principles of “broken immune tolerance” via T cell based immunotherapy for prostate cancer. The Simons lab invented GM-CSF genetically engineered vaccines for prostate cancer in rodents and humans for these studies, and subsequently Simons’ clinical team took the biotechnology into the world’s first human gene therapy clinical trials for advanced prostate cancer at Johns Hopkins.
Brian Patrick Monahan is the Attending Physician of the United States Congress and the United States Supreme Court and holds the rank of rear admiral in the United States Navy. Monahan was selected by the leadership of the Congress and nominated to the position and rank by United States President Barack Obama in January 2009. He previously served as the director of hematology and medical oncology at the National Naval Medical Center. He is a Master of The American College of Physicians and a Member of the Academy of Medicine.
Professor Charles Mark Lwanga Olweny, MBChB, MMed, MD, FRACP, is a Ugandan physician, oncologist, academic and medical researcher. Currently he is a professor of medicine and Immediate past vice-chancellor at Uganda Martyrs University, based at Nkozi, Mpigi District, in Central Uganda.
Edith A. Pérez is a Puerto Rican hematologist-oncologist. She is the Serene M. and Frances C. Durling Professor of Medicine at the Mayo Clinic Alix School of Medicine.
James Frederick Holland was an American physician and Distinguished Professor of Neoplastic Diseases at the Icahn School of Medicine at Mount Sinai in New York. Early in his career, he had worked for the National Cancer Institute and Roswell Park Comprehensive Cancer Center.
Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.
Mary-Ellen Taplin, is a research oncologist at Dana Farber Cancer Institute and Brigham and Women's Hospital in Harvard's Longwood Medical and Academic Area.
Bruce Allan Chabner is a professor of medicine at Harvard Medical School and Director of Clinical Research at the MGH Cancer Center at Massachusetts General Hospital. His research focuses on anti-folate drugs for the treatment of cancer.
Janet Woodcock is an American physician and former Acting Commissioner of the U.S. Food and Drug Administration (FDA). She joined the FDA in 1986, and has held a number of senior leadership positions there, including terms as the Director of Center for Drug Evaluation and Research (CDER) from 1994 to 2004 and 2007 to 2021.
Joseph Rocco Bertino was a researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research is focused on the treatment of lymphoma.
Oliver Sartor is an American oncologist and research scientist. He is currently the assistant dean for oncology and the C.E. and Bernadine Laborde Professor of Cancer Research, Medicine and Urology Departments at the Tulane School of Medicine in New Orleans, Louisiana. His research has mainly focused on translational science and clinical research trials of advanced prostate cancer since 1990 and he is recognized as an expert in that field through his contributions to the practice and the publishing of over 500 peer-reviewed articles and numerous book chapters and reviews. Sartor also serves as the editor-in-chief of the bimonthly journal Clinical Genitourinary Cancer that mainly focuses on research in genitourinary oncology.
Maha H. Hussain is the Genevieve E. Teuton Professor of Medicine and deputy director of the Lurie Comprehensive Cancer Center at Northwestern University's Feinberg School of Medicine. She is an oncologist focusing on genitourinary cancers.
Peter Marks is an American hematologist oncologist serving as the director of the Center for Biologics Evaluation and Research within the Food and Drug Administration. He was appointed to the position in 2016 after previously serving as deputy director. He has two children a daughter and a son. Dr. Marks resides in Washington, D.C., with his wife.
Brigitte C. Widemann is German-American pediatric oncologist. She is chief of the pediatric oncology branch and clinical deputy director of the center for cancer research at the National Cancer Institute. She is also the special advisor to the NCI director for childhood cancer.
References
- 1 2 3 Printz, Carrie (June 2021). "First person profile: Richard Pazdur, MD: The founding director of the FDA's Oncology Center of Excellence has long spearheaded major initiatives to improve oncology drug development". Cancer. 127 (11): 1731–1733. doi: 10.1002/cncr.33631 . PMID 33970487. S2CID 234346640.
- ↑ Commissioner, Office of the (23 April 2019). "Richard Pazdur". U.S. Food and Drug Administration.
- ↑ "FDA officially launches its Oncology Center of Excellence (OCE)". WEP Clinical. 31 January 2017. Retrieved 23 May 2022.
- ↑ Hagen, Tony (30 December 2019). "Pazdur Followed the Pathway of Greatest Resistance to the FDA". OncologyLive.
| Authority control: Academics |
|---|
